Contact Us

Yes. CD137 rescue experiments require attention to its surface receptor topology: • Construct design: use a codon-modified TNFRSF9 sequence with a C-terminal tag (HA, FLAG) on the cytoplasmic domain. CD137 is a type I membrane protein — the N-terminal signal peptide and cysteine-rich extracellular domain must be preserved. • Surface expression validation: confirm exogenous CD137 surface localization by flow cytometry with anti-CD137 antibodies before functional assays. • Signaling domain mutant rescue: cytoplasmic TRAF-binding motif mutations dissect ligand-binding from intracellular signaling functions. • Functional readout: rescue should restore antibody and 4-1BBL binding (flow cytometry, SPR/BLI binding assays). HEK293 transduces efficiently with lentivirus and is a standard heterologous expression system for type I membrane receptor characterization.

The choice depends on whether you are studying TRAIL biology or producing recombinant TRAIL for apoptosis research. Note that TNFSF10 (TRAIL) is normally expressed by immune cells and induced by interferons; it acts on death receptors DR4/DR5 to trigger extrinsic apoptosis selectively in tumor cells. The Knockout line in HEK293 is most useful for biochemical and reagent production purposes; HEK293 is widely used for recombinant TRAIL expression. Overexpression is generally more functionally informative than knockout for TRAIL research in HEK293 — recombinant TRAIL production for cancer cell apoptosis assays is the predominant application. The EDITGENE Knockout line is useful as a negative control for confirming on-target activity of TRAIL receptor agonists in clinical development, and for background-free recombinant TRAIL expression. Rescue with wild-type or specific receptor-binding-modified TRAIL variants (e.g., DR5-selective TRAIL) enables receptor selectivity studies.

Yes. TRAIL rescue experiments require attention to trimerization and receptor selectivity: • Construct design: use a codon-modified TNFSF10 sequence with a C-terminal tag (FLAG, HA, His-tag). TRAIL is a type II membrane protein; the soluble extracellular domain (~residues 95-281) is the typical functional construct. • Receptor selectivity rescue: TRAIL binds DR4, DR5, and decoy receptors DcR1/DcR2 — engineered DR5-selective or DR4-selective TRAIL variants are valuable for receptor-specific apoptosis studies. • Trimerization validation: TRAIL functions as a homotrimer with bound zinc — proper assembly should be confirmed before functional assays. • Functional readout: rescue should restore secreted soluble TRAIL production (ELISA) and DR4/DR5-mediated apoptosis induction (caspase-8 cleavage assays in TRAIL-sensitive target cells). HEK293 is the standard cell line for recombinant TRAIL production for cancer apoptosis research applications.

The choice depends on whether you are studying TLR3/TLR4 MyD88-independent signaling or TICAM1's role in antiviral and inflammatory responses. The Knockout line is appropriate for asking whether TICAM1 (TRIF) is required for type I IFN induction downstream of TLR3 (dsRNA sensing) and TLR4 (LPS sensing — endosomal arm). Overexpression is useful for testing whether elevated TICAM1 is sufficient to drive IFN responses. For antiviral immunity research, the EDITGENE TICAM1 Knockout in A-549 is highly relevant — A-549 is widely used in respiratory virus infection studies, and TICAM1 mediates IFN induction following dsRNA detection during many viral infections. Rescue with wild-type or TIR-domain-deleted TICAM1 separates adaptor function from other signaling roles.

Yes. TICAM1 rescue experiments require attention to TIR domain function and adaptor recruitment: • Construct design: use a codon-modified TICAM1 sequence with a C-terminal tag (FLAG, HA). TICAM1 contains an N-terminal TIR domain critical for TLR3/TLR4 receptor binding. • TIR domain mutant rescue: TIR-domain point mutations (e.g., P434H) disrupt receptor binding and serve as specificity controls for adaptor function. • Functional readout: rescue should restore poly(I:C)-induced IFN-β reporter activation and ISG expression in A-549. • Combined assay design: rescue should be tested under TLR3 (poly(I:C)) and TLR4 (LPS) stimulation conditions to confirm both signaling pathways are restored. A-549 transduces efficiently with lentivirus and supports stable rescue line generation in the respiratory virus research context.

The choice depends on whether you are studying TEAD2 as a YAP/TAZ transcriptional partner in Hippo signaling or its specific role in cancer biology, particularly NSCLC. The Knockout line is appropriate for asking whether TEAD2 is required for YAP/TAZ-mediated transcription in A-549 — a context where Hippo pathway dysregulation is well-documented. Overexpression is useful for testing TEAD2 sufficiency or for studying TEAD2 in cancer contexts where it is amplified or overexpressed. Important consideration: TEAD1-4 share substantial functional redundancy as YAP/TAZ partners. Single TEAD2 knockout in A-549 may show mild phenotypes if TEAD1, TEAD3, and TEAD4 compensate. The EDITGENE Knockout line is most informative when combined with assessment of remaining TEAD paralog expression. Rescue with wild-type or YAP-binding-deficient TEAD2 is the standard approach for assigning observed phenotypes to YAP/TAZ partnership. TEAD inhibitors (palmitate-binding pocket compounds) are in clinical development, making this knockout valuable as a specificity control.

Yes. TEAD2 rescue experiments require attention to YAP/TAZ binding and palmitoylation: • Construct design: use a codon-modified TEAD2 sequence with a small N- or C-terminal tag (FLAG, HA). TEAD2 contains an N-terminal TEA DNA-binding domain and C-terminal YAP/TAZ-binding domain. • YAP-binding-deficient rescue: specific mutations at the YAP-binding interface (e.g., Y429H equivalents) separate YAP/TAZ-dependent functions from DNA-binding activities. • Palmitoylation studies: TEAD family proteins are auto-palmitoylated at a conserved cysteine — palmitoylation-deficient mutants (C-to-S in the lipid-binding pocket) test the role of this modification, which is also the target of clinical TEAD inhibitors. • TEAD paralog compensation: rescue interpretation should account for TEAD1/3/4 expression in A-549. A-549 transduces efficiently with lentivirus and supports stable rescue line generation.

The choice depends on whether you are studying TCF12 (HEB) as a class I bHLH transcription factor or its emerging roles in colorectal cancer and stem cell biology. The Knockout line is appropriate for asking whether TCF12 is required for E-box-dependent gene regulation, dimerization with class II bHLH factors, or specific developmental gene programs. Overexpression is useful for testing whether elevated TCF12 is sufficient to alter dimerization partner availability or to drive specific transcriptional programs. Important consideration: TCF12 shares substantial functional overlap with E2A (TCF3) and HEB-T variants — single TCF12 knockout may show modest phenotypes if paralog compensation occurs. The EDITGENE Knockout line in HCT 116 is particularly relevant for colorectal cancer research, where TCF12 has been implicated in EMT and metastasis. Rescue with wild-type, dimerization-deficient, or DNA-binding-deficient TCF12 is the standard approach for dissecting structural contributions to function.

Yes. TCF12 rescue experiments require attention to dimerization and DNA binding: • Construct design: use a codon-modified TCF12 sequence with a small C-terminal tag (FLAG, HA). TCF12 has multiple alternative splice isoforms — choose the isoform appropriate to the experimental context. • Dimerization-deficient rescue: bHLH domain mutations that disrupt heterodimerization with class II bHLH partners separate DNA-binding from partnership-dependent functions. • DNA-binding-deficient rescue: basic region mutations abolish E-box binding while preserving dimerization, enabling structure-function dissection. • Paralog considerations: E2A (TCF3) expression analysis in rescue cells helps interpret class I bHLH family redundancy. HCT 116 transduces efficiently with lentivirus and supports stable rescue line generation; the MSI-high background should be considered in colorectal cancer context studies.

The choice depends on whether you are studying TNFR2-specific signaling — distinct from TNFR1 — or its emerging role in Treg biology and tumor immunity. The Knockout line is appropriate for asking whether TNFR2 is required for non-classical TNF signaling, including TRAF2-mediated NF-κB activation and anti-apoptotic signaling. Overexpression is useful for testing whether elevated TNFR2 is sufficient to enhance these pathways. For TNF biology research, the EDITGENE Knockout in HAP1 is particularly informative when combined with the parallel TNFR1 knockout — comparison of single and combined knockouts dissects receptor-specific TNF functions, since TNF binds both receptors with different affinities and signaling consequences. Rescue with wild-type or signaling domain-deleted TNFR2 is the standard approach for assigning observed phenotypes to specific TNFR2 signaling outputs.

Yes. TNFR2 rescue experiments require attention to receptor topology and signaling specificity: • Construct design: use a codon-modified TNFRSF1B sequence with a cytoplasmic C-terminal tag (FLAG, HA). TNFR2 is a type I membrane protein — the extracellular cysteine-rich domains and the cytoplasmic tail must both be preserved. • Surface expression validation: confirm exogenous TNFR2 surface localization by flow cytometry before downstream signaling assays. • Signaling domain mutant rescue: TRAF2-binding-deficient mutations separate ligand binding from intracellular signaling functions. • Functional readout: rescue should restore TRAF2-mediated NF-κB activation and TNFR2-specific gene expression patterns. HAP1-specific considerations: • Diploidization: HAP1 cells gradually diploidize during extended culture — confirm ploidy by flow cytometry at the time of phenotypic assay. • Integration site sensitivity: position effects on transgene expression are more pronounced in near-haploid backgrounds; generating multiple independent rescue clones is strongly recommended. • Transduction efficiency: HAP1 transduces with lentivirus at moderate efficiency — increase MOI compared to standard immortalized lines.

The choice depends on whether you are studying TAOK2's role in MAP kinase signaling, autism-spectrum-related neuronal biology, or DNA damage response. The Knockout line is appropriate for asking whether TAOK2 is required for these pathways — TAOK2 has been implicated in 16p11.2 deletion-associated neurodevelopmental phenotypes. Overexpression is useful for testing whether elevated TAOK2 activity drives specific signaling outputs or for studying 16p11.2 duplication-related phenotypes. Important consideration: TAOK1 and TAOK3 share substantial overlap with TAOK2 in MAPK signaling. The EDITGENE Knockout line is most informative when paralog status is assessed; combined analysis with the parallel TAOK3 knockout enables family-specific dissection. Rescue with wild-type, kinase-dead, or autism-associated variant TAOK2 enables mechanistic and disease-modeling studies.

The choice depends on whether you are studying TEC kinase's role in immune cell signaling or its emerging functions outside hematopoietic contexts. Important consideration: TEC kinase is normally expressed in T cells, mast cells, and other hematopoietic lineages — HAP1 (myeloid origin) has detectable but modest TEC expression. The Knockout line is appropriate for asking whether TEC contributes to signaling in this hematopoietic-related background, but physiological TEC functions are best studied in T cell or mast cell systems. Overexpression in HAP1 may be more informative for biochemical studies of TEC kinase activity, substrate phosphorylation, and inhibitor specificity testing. The EDITGENE Knockout line is useful as a clean genetic background for distinguishing TEC from its family paralogs (BTK, ITK, BMX, TXK), and as a specificity control for TEC kinase inhibitors. Rescue with wild-type or kinase-dead TEC is the standard control.

Yes. TEC rescue experiments require attention to its multi-domain architecture: • Construct design: use a codon-modified TEC sequence with a C-terminal tag (FLAG, HA). TEC contains PH, SH3, SH2, and kinase domains — all must be preserved. • Kinase-dead rescue: the K398R mutation in the active site abolishes catalytic activity and is the standard specificity control. • Domain-specific mutants: PH-domain mutations (PI(3,4,5)P3-binding-deficient) and SH3/SH2 domain mutations enable dissection of membrane recruitment versus substrate engagement. • Inhibitor selectivity controls: TEC family inhibitors often show cross-reactivity — rescue with wild-type or specific inhibitor-resistant TEC variants is valuable for assessing on-target activity. HAP1-specific considerations: • Diploidization: HAP1 cells gradually diploidize during extended culture — confirm ploidy by flow cytometry at the time of phenotypic assay. • Integration site sensitivity: position effects on transgene expression are more pronounced in near-haploid backgrounds; generating multiple independent rescue clones is strongly recommended. • Transduction efficiency: HAP1 transduces with lentivirus at moderate efficiency — increase MOI compared to standard immortalized lines.

The choice depends on whether you are studying TNFR1-specific signaling — distinct from TNFR2 — or its role in inflammatory and cell death pathways. The Knockout line is appropriate for asking whether TNFR1 is required for classical TNF signaling, including death-domain-mediated apoptosis/necroptosis and NF-κB activation. Overexpression is useful for studying TNFR1-driven gain-of-function or modeling TRAPS (TNFR1-associated periodic syndromes) mutations. For TNF biology research, the EDITGENE Knockout in HAP1 is the standard tool — TNFR1 is the principal mediator of TNF cytotoxicity and inflammatory signaling. Combined analysis with the TNFR2 knockout (also available) enables comprehensive receptor-specific dissection. Rescue with wild-type, death-domain-deleted, or TRAPS-associated mutant TNFR1 enables disease modeling and signaling pathway dissection.